De­nali un­veils new way of cross­ing blood brain bar­ri­er as the big neu­ro­science bet en­ters its clin­i­cal years

Five years ago, as much of phar­ma be­gan leav­ing neu­ro­science, three big-name sci­en­tists from Genen­tech and some A-list in­vestors, in­clud­ing ARCH and Flag­ship, made a $217 mil­lion bet that new ge­net­ic in­sights and a re­liance on bio­mark­ers could bring them suc­cess. They called it De­nali Ther­a­peu­tics.

Still, De­nali faced the prob­lem that neu­ro­science de­vel­op­ers have faced for decades: How do you get a large mol­e­cule across the blood-brain bar­ri­er, a nat­ur­al de­fense evolved pre­cise­ly to keep them out? En­zyme re­place­ment ther­a­py, for in­stance, would be a great can­di­date to treat sev­er­al neu­ro­log­i­cal dis­or­ders, but en­zymes can’t cross the bar­ri­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA